Only 33% TRUST US Health Agencies. WHY?

America’s health agencies face a critical trust deficit as conflicts of interest permeate the very institutions tasked with safeguarding public health.

At a Glance

  • Only 33% of Americans express high trust in the U.S. health system according to a 2023 Gallup poll
  • The FDA’s independence has been questioned since the 1992 Prescription Drug User Fee
  • Act allowed pharmaceutical companies to pay for faster drug approvals
  • Multiple FDA commissioners and CDC directors have maintained significant financial ties to industries they regulated
  • The CDC Foundation receives corporate funding, raising concerns about potential influence on public health decisions
  • Pharmaceutical industry heavily lobbies Congress while funding medical research published in major journals

The Crumbling Foundation of Health Agency Trust

Trust in America’s health agencies has steadily eroded over decades, with concerns about conflicts of interest (COIs) at the heart of this decline. The Food and Drug Administration’s reputation began to deteriorate with the passage of the 1992 Prescription Drug User Fee Act, which permitted pharmaceutical companies to pay fees directly to the FDA to expedite drug approvals.

This fundamental shift raised serious questions about whether the agency could maintain its independence while accepting millions from the very companies it was meant to regulate. Three decades later, these concerns have only intensified as financial entanglements between health agencies and industry have become more complex and pervasive.

Revolving Doors: Leadership with Industry Ties

The FDA’s leadership has repeatedly come under scrutiny for its deep connections to the pharmaceutical industry. Former FDA commissioners including Dr. Scott Gottlieb, Dr. Robert Califf, and Dr. Margaret Hamburg have all maintained significant financial relationships with drug companies, either before their appointments, after leaving office, or both.

These connections raise legitimate questions about potential bias in decision-making that affects millions of Americans. The pattern of commissioners moving between regulatory roles and lucrative industry positions creates an appearance of impropriety that undermines public confidence in the agency’s decisions.

The Centers for Disease Control and Prevention faces similar challenges. The CDC Foundation, established by Congress in 1992, operates as a vehicle for private-sector donations to CDC initiatives. While this provides valuable funding, it creates potential conflicts when corporations with vested interests in public health policies become major donors.

Former CDC director Dr. Brenda Fitzgerald was forced to resign after revelations about her investments in tobacco and health insurance stocks emerged. Previous directors Dr. Tom Frieden and Dr. Julie Gerberding have also faced allegations of conflicts of interest, with Dr. Gerberding notably becoming president of Merck’s vaccine division after leaving the CDC.

Corporate Influence Extends Beyond Agencies

The pharmaceutical industry’s influence extends well beyond health agencies, creating a comprehensive web of potential conflicts. The industry maintains one of the largest lobbying operations in Washington, with many congressional representatives receiving substantial campaign contributions from drug companies. This financial relationship raises concerns about Congress’s ability to provide effective oversight of the FDA and CDC. Meanwhile, medical journals increasingly publish research funded by pharmaceutical companies, potentially skewing the scientific evidence that guides health policy decisions and medical practice guidelines.

This widespread infiltration of corporate interests into healthcare institutions has created a crisis of confidence. According to a 2023 Gallup poll, only 33% of Americans express “a great deal” or “quite a lot” of trust in the U.S. healthcare system.

This trust deficit directly impacts public health outcomes, as citizens grow skeptical of medical advice, recommended treatments, and preventative measures endorsed by agencies they perceive as compromised by industry influence. The erosion of trust ultimately threatens the system’s ability to function effectively during both routine operations and public health emergencies.

Rebuilding Trust Through Transparency and Reform

Restoring confidence in health agencies requires systematic reform addressing the root causes of public skepticism. Greater transparency in agency funding, stricter conflict of interest policies for leadership, and stronger barriers between regulators and industry are essential first steps.

Academic health systems can play a crucial role in rebuilding trust by demonstrating independence from industry influence and by prioritizing community partnerships that address social determinants of health. Programs like MedStar Health’s Community Violence Intervention Program and D.C. Safe Babies Safe Moms Program exemplify how healthcare institutions can rebuild community trust through direct engagement.

The relationship between healthcare providers and patients has fundamentally changed in the information age. Providers must adapt from being sole authorities to becoming trusted partners who help interpret and apply medical information.

This shift requires genuine engagement with patient perspectives and a commitment to shared decision-making. By placing patient and community needs at the center of healthcare actions and research, and by establishing clear boundaries between regulatory functions and industry interests, America’s health institutions can begin the long process of rebuilding the trust necessary for effective public health outcomes.

RELATED ARTICLESMORE FROM AUTHOR